Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis
Comparison of 3g Versus 2g Mycophenolate Mofetil in Combination With Tacrolimus on Progression of Chronic Histology Changes in Kidney Transplant Recipients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
HR
-
Zagreb, HR, Croatia, 10000
- Clinical Hospital Merkur
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- first kidney or kidney-pancreas transplantation
- CDC PRA <=20%
Exclusion Criteria:
- dual kidney transplantation
- AB0 incompatible transplantation
- 0 biopsy ci, ct, cv, or ah score >=2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: MMF 3g daily
|
Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant.
Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
|
|
Active Comparator: MMF 2 g daily
|
Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant.
Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression of interstitial fibrosis (ci)
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Graft loss
Time Frame: 1 year
|
1 year
|
|
Patient survival
Time Frame: 1 year
|
1 year
|
|
Estimated glomerular filtration rate
Time Frame: 1 year
|
1 year
|
|
Time to first acute rejection episode
Time Frame: up to 1 year
|
up to 1 year
|
|
Progression of other chronic scores
Time Frame: 1 year
|
1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of infections requiring hospitalization
Time Frame: 1 year
|
1 year
|
|
|
Frequency of CMV viremia
Time Frame: 1 year
|
1 year
|
|
|
Frequency of BK viremia
Time Frame: 1 year
|
1 year
|
|
|
Frequency of BK nephropathy
Time Frame: 1 year
|
1 year
|
|
|
Development of donor-specific antibodies
Time Frame: 1 year
|
1 year
|
|
|
Renal morphology and hemodynamics assessed by ultrasound
Time Frame: 1 year
|
Subset of study patients
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHMerkur
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.